Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion

Description

The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet and one with medication called "cabergoline" which are taken immediately after their procedure. Researchers will compare groups to see if there are any significant differences in breast symptoms.

Conditions

Lactation Suppressed, Second Trimester Abortion

Study Overview

Study Details

Study overview

The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet and one with medication called "cabergoline" which are taken immediately after their procedure. Researchers will compare groups to see if there are any significant differences in breast symptoms.

Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion: a Randomized Controlled Trial

Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion

Condition
Lactation Suppressed
Intervention / Treatment

-

Contacts and Locations

Chicago

Northwestern Medical Center, Chicago, Illinois, United States, 60611

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * pregnant individuals seeking termination of pregnancy after 16w0d gestation and up to 19w6d gestation. this includes management of intrauterine demises
  • * ages 18 to 50
  • * con provide informed consent in English
  • * Age under 18 or above 50
  • * gestational ages before 16 weeks 0 days or after 20 weeks 0 days
  • * unable to provide written consent in English
  • * hypertensive disorder
  • * uncontrolled hypertension or known hypersensitivity to ergot derivatives
  • * History of cardiac valvular disorders
  • * history of pulmonary fibrosis
  • * documented bipolar schizophrenia
  • * documented allergy to medication, including lactose intolerance (placebo pill involves lactose)

Ages Eligible for Study

18 Years to 50 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Northwestern University,

Study Record Dates

2024-06-30